FindTrial
Sign In

Alfentanil combined with different sedative drugs for ED95 in gynecological day surgery

Alfentanil combined with different sedative drugs for ED95 in gynecological day surgery

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100042479
Enrollment
Unknown
Registered
2021-01-22
Start date
2021-02-01
Completion date
Unknown
Last updated
2021-04-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gynecological day surgery

Interventions

Group R1:Fentanyl 7.8ug/kg + Remazolam
Group R2:Fentanyl 8.8ug/kg + Remazolam
Group R3:Fentanyl 10ug/kg + Remazolam
Group R4:Fentanyl 11.3ug/kg +Remazolam
Group R5:Fentanyl 12.8ug/kg +Remazolam
Group B1:Fentanyl 7.8ug/kg + propofol
Group B2:Fentanyl 8.8ug/kg + propofol
Group B3:Fentanyl10ug/kg + propofol
Group B4:Fentanyl11.3ug/kg + propofol
Group B5:Fentanyl 12.8ug/kg + propofol

Sponsors

359 Shiji Road, Yuhang, Hangzhou, Zhejiang, China
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 45 Years

Inclusion criteria

Inclusion criteria: Agree to this study Age: 18-40 years old; BMI: 18-25; ASA I - II female patients; gestational age: 4-7 weeks; planned painless abortion, hysteroscopy or other day gynecological surgery

Exclusion criteria

Exclusion criteria: Severe cardiovascular and cerebrovascular diseases; Hepatitis; kidney disease, severe anemia and malnutrition; endocrine history; History of chronic pain; history of mental illness or psychotropic drug dependence; patients allergic to alfentanil, propofol or remazolam.

Design outcomes

Primary

MeasureTime frame
Body movement response;Vital signs;Drug dosage;Waking time;—

Secondary

MeasureTime frame
Postoperative pain;Postoperative nausea and vomiting;—

Countries

china

Contacts

Public ContactLinda Jin
littledandan_927@sina.com15967106092

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026